Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long‐acting β 2 ‐agonists in obstructive lung diseases: a population‐based, observational study
Open Access
- 18 June 2014
- journal article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 68 (7), 812-819
- https://doi.org/10.1111/ijcp.12473
Abstract
In 2010, the Icelandic government introduced a new cost-saving policy that limited reimbursement of fixed inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations. This population-based, retrospective, observational study assessed the effects of this policy change by linking specialist/primary care medical records with data from the Icelandic Pharmaceutical Database. The policy change took effect on 1 January 2010 (index date); data for the year preceding and following this date were analysed in 8241 patients with controlled/partly controlled asthma and/or chronic obstructive pulmonary disease (COPD) who had been dispensed an ICS/LABA during 2009. Oral corticosteroid (OCS) and short-acting β2-agonist (SABA) use, and healthcare visits, were assessed pre- and post-index. The ICS/LABA reimbursement policy change led to 47.8% fewer fixed ICS/LABA combinations being dispensed during the post-index period among patients whose asthma and/or COPD was controlled/partly controlled during the pre-index period. Fewer ICS monocomponents were also dispensed. A total of 48.6% of patients were no longer receiving any respiratory medications after the policy change. This was associated with reduced disease control, as demonstrated by more healthcare visits (44.0%), and more OCS (76.3%) and SABA (51.2%) dispensations. Overall, these findings demonstrate that changes in healthcare policy and medication reimbursement can directly impact medication use and, consequently, clinical outcomes and should, therefore, be made cautiously.Keywords
Funding Information
- astra zeneca
This publication has 24 references indexed in Scilit:
- Potential negative consequences of non‐consented switch of inhaled medications and devices in asthma patientsInternational Journal of Clinical Practice, 2013
- Are inhaled longacting β2 agonists detrimental to asthma?The Lancet Respiratory Medicine, 2013
- Long-Acting β2-Agonist Step-off in Patients With Controlled AsthmaArchives of Internal Medicine, 2012
- Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting β-agonist inhaler therapy in asthmaJournal of Allergy and Clinical Immunology, 2010
- What happens to patients who have their asthma device switched without their consent?Primary Care Respiratory Journal, 2010
- Inhaled corticosteroids for asthma: impact of practice level device switching on asthma controlBMC Pulmonary Medicine, 2009
- Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary DiseaseDrugs, 2009
- Short-acting β2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting β2-agonist or salmeterol/fluticasone propionate combinationInternational Journal of Clinical Practice, 2005
- Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary diseaseEuropean Respiratory Journal, 2003
- Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.European Respiratory Journal, 2003